High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 3, 2009, Pages 289-295

  Giraud, C ^a   Decleves X ^b   Perrot, J Y ^c   Manceau, S ^a   Pannier, E ^d   Firtion, G ^d   Morini, J P ^e   Chappuy, H ^f   Batteux, F ^a   Chouzenoux, S ^a   Scherrmann, J M ^b   Blanche, S ^f   Treluyer J M ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c HÔTEL DIEU   (France)

^d NONE   (France)

^e Paris Descartes University   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 DIETHYLOXACARBOCYANIN IODIDE; EFAVIRENZ; GLYCOPROTEIN P; IODINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NATURAL KILLER CELL; NEWBORN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; P-GLYCOPROTEIN; YOUNG ADULT;

EID: 60349107784     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.221     Document Type: Article

References (38)

1. Fromm, M.F. Importance of P-glycoprotein for drug disposition in humans. Eur. J. Clin. Invest. 33 (suppl. 2), 6-9 (2003).
2. Kim, R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. 34, 47-54 (2002).
3. Marzolini, C., Paus, E., Buclin, T. & Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
4. Jones, K., Hoggard, P.G., Sales, S.D., Khoo, S., Davey, R. & Back, D.J. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15, 675-681 (2001).
5. Meaden, E.R. et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chem. 50, 583-588 (2002).
6. Ford, J., Khoo, S.H. & Back, D.J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chem. 54, 982-990 (2004).
7. Chaudhary, P.M., Mechetner, E.B. & Roninson, I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80, 2735-2739 (1992).
8. Klimecki, W.T., Futscher, B.W., Grogan, T.M. & Dalton, W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83, 2451-2458 (1994).
9. Lucia, M.B., Rutella, S., Leone, G., Vella, S. & Cauda, R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J. Acquir. Immune Defic. Syndr. 27, 321-330 (2001).
10. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
11. Scotto, K.W. Transcriptional regulation of ABC drug transporters. Oncogene 22, 7496-7511 (2003).
12. Kim, W.Y. & Benet, L.Z. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm. Res. 21, 1284-1293 (2004).
13. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. & Kauffman, R.E. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
14. Pilarski, L.M., Paine, D., McElhaney, J.E., Cass, C.E. & Belch, A.R. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am. J. Hematol. 49, 323-335 (1995).
15. Machado, C.G., Calado, R.T., Garcia, A.B. & Falcao, R.P. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz. J. Med. Biol. Res. 36, 1653-1657 (2003).
16. Falcao, R.P. & De Santis, G.C. Age-associated changes of memory (CD45RO+) and naive (CD45R+) T cells. Braz. J. Med. Biol. Res. 24, 275-279 (1991).
17. Ludescher, C., Pall, G., Irschick, E.U. & Gastl, G. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br. J. Haematol. 101, 722-727 (1998).
18. Axiotis, C.A., Guarch, R., Merino, M.J., Laporte, N. & Neumann, N.D. P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab. Invest. 65, 577-581 (1991).
19. Drach, D. et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80, 2729-2734 (1992).
20. Vasquez, E.M. et al. An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. Transplant. Proc. 37, 175-177 (2005).
21. Klimecki, W.T., Taylor, C.W. & Dalton, W.S. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J. Clin. Immunol. 15, 152-158 (1995).
22. Grubeck-Loebenstein, B. Changes in the aging immune system. Biologicals 25, 205-208 (1997).
23. Fakhoury, M. et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 33, 1603-1607 (2005).
24. Albermann, N. et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70, 949-958 (2005).
25. Haber, D.A. Multidrug resistance (MDR1) in leukaemia: is it time to test? Blood 79, 295-298 (1992).
26. Lossos, I.S., Czerwinski, D.K., Wechser, M.A. & Levy, R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17, 789-795 (2003).
27. Treluyer, J.M., Jacqz-Aigrain, E., Alvarez, F. & Cresteil, T. Expression of CYP2D6 in developing human liver. Eur. J. Biochem. 202, 583-588 (1991).
28. McClean, S. & Hill, B.T. Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur. J. Cancer 29, 2243-2248 (1993).
29. Yague, E. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J. Biol. Chem. 278, 10344-10352 (2003).
30. Gómez-Martinez, A. et al. Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol. Cancer Res. 5, 641-653 (2007).
31. Lucia, M.B., Rutella, S., Leone, G., Larocca, L.M., Vella, S. & Cauda, R. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J. Acquir. Immune Defic. Syndr. 30, 369-378 (2002).
32. Meaden, E.R., Hoggard, P.G., Maher, B., Khoo, S.H. & Back, D.J. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res. Hum. Retroviruses 17, 1329-1332 (2001).
33. Andreana, A., Aggarwal, S., Gollapudi, S., Wien, D., Tsuruo, T. & Gupta, S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 12, 1457-1462 (1996).
34. Lucia, M.B., Cauda, R., Landay, A.L., Malorni, W., Donelli, G. & Ortona, L. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res. Hum. Retroviruses 11, 893-901 (1995).
35. Chandler, B. et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33, 551-556 (2003).
36. Störmer, E., von Moltke, L.L., Perloff, M.D. & Greenblatt, D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19, 1038-1045 (2002).
37. Chaudhary, P.M. & Roninson, I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85-94 (1991).
38. Park, S.W., Lomri, N., Simeoni, L.A., Fruehauf, J.P. & Mechetner, E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A 53, 67-78 (2003).